Merck Inks Supply Pact With Singapore For Its Oral COVID-19 Antiviral: Reuters - Merck & Co (NYSE:MRK)

Reuters reported that Merck & Co Inc MRK has announced a supply and purchase agreement to provide Singapore with access to its experimental oral COVID-19 antiviral drug.
Molnupiravir is designed to introduce errors into the virus's genetic code and be the first oral antiviral medication for COVID-19.
Merck is seeking approval from the FDA. The financial details were not disclosed.
The European Medicines Agency will also consider launching a rolling review of Merck's COVID-19 pill in the coming days.
Singapore's health ministry did not immediately respond to a request for confirmation of the Merck agreement.
Australia has also bought the Merck COVID-19 pill, while Thailand, South Korea, Taiwan, and Malaysia have bought it.
The Philippines hopes its trial of the pill would allow it access.
The rush to order the drug comes after data from interim clinical trials was released on Friday.
Related Link: Merck's COVID-19 Oral Antiviral Cuts Risk of Hospitalization, Death By 50%.
Price Action: MRK stock is down 1.59% at $80.30 during the premarket session on the last check Wednesday.